DE69630779D1 - Therapeutische verwendungen von glucan - Google Patents

Therapeutische verwendungen von glucan

Info

Publication number
DE69630779D1
DE69630779D1 DE69630779T DE69630779T DE69630779D1 DE 69630779 D1 DE69630779 D1 DE 69630779D1 DE 69630779 T DE69630779 T DE 69630779T DE 69630779 T DE69630779 T DE 69630779T DE 69630779 D1 DE69630779 D1 DE 69630779D1
Authority
DE
Germany
Prior art keywords
glucan
compositions
therapeutic uses
glucans
water insoluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630779T
Other languages
English (en)
Other versions
DE69630779T2 (de
Inventor
Edmund Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tr Therapeutics Inc Us
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Application granted granted Critical
Publication of DE69630779D1 publication Critical patent/DE69630779D1/de
Publication of DE69630779T2 publication Critical patent/DE69630779T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
DE69630779T 1995-03-13 1996-03-13 Therapeutische verwendungen von glucan Expired - Lifetime DE69630779T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN1661A AUPN166195A0 (en) 1995-03-13 1995-03-13 Process for glucan extraction
AUPN166195 1995-03-13
PCT/AU1996/000138 WO1996028476A1 (en) 1995-03-13 1996-03-13 Process for glucan preparation and therapeutic uses of glucan

Publications (2)

Publication Number Publication Date
DE69630779D1 true DE69630779D1 (de) 2003-12-24
DE69630779T2 DE69630779T2 (de) 2004-09-23

Family

ID=3786016

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630779T Expired - Lifetime DE69630779T2 (de) 1995-03-13 1996-03-13 Therapeutische verwendungen von glucan

Country Status (9)

Country Link
US (5) US6242594B1 (de)
EP (1) EP0815144B1 (de)
JP (2) JP4197736B2 (de)
AT (1) ATE254634T1 (de)
AU (1) AUPN166195A0 (de)
DE (1) DE69630779T2 (de)
ES (1) ES2211943T3 (de)
GB (1) GB2314850B (de)
WO (1) WO1996028476A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE275959T1 (de) * 1992-05-19 2004-10-15 Graham Edmund Kelly Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
DE19710368A1 (de) * 1997-03-13 1998-09-17 Henkel Kgaa Verwendung von wasserlöslichen beta-Glucanen als Wirkstoffe zur Herstellung von therapeutischen Mitteln zur Hautbehandlung
AU1944599A (en) * 1997-12-24 1999-07-19 Shaklee Corporation Composition with high efficiency skin protection from damaging effects of ultraviolet light
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
US8501710B2 (en) * 1999-03-12 2013-08-06 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
DE19911058B4 (de) * 1999-03-12 2004-09-30 Biotec Asa Verwendung von nanoskaligen wasserlöslichen β-(1,3)-Glucanen
US8912165B2 (en) 1999-03-12 2014-12-16 Biotec Pharmacon Asa Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents
DE19911055A1 (de) * 1999-03-12 2000-09-21 Cognis Deutschland Gmbh Verwendung von oberflächenaktiven Gemischen
US6875754B1 (en) * 1999-03-12 2005-04-05 Biotec Asa Use of water-soluble β-(1,3) glucans as agents for producing therapeutic skin treatment agents
DE19917744A1 (de) 1999-04-20 2000-10-26 Cognis Deutschland Gmbh Dekorative kosmetische Zubereitungen
WO2001005412A1 (fr) 1999-07-21 2001-01-25 Kabushiki Kaisha Yakult Honsha Agents de reduction du cholesterol, inhibiteurs de production d'acide biliaire secondaire, aliments et boissons
US6541678B2 (en) * 1999-09-27 2003-04-01 Brennen Medical, Inc. Immunostimulating coating for surgical devices
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
JP2001354570A (ja) * 2000-06-15 2001-12-25 Ichimaru Pharcos Co Ltd 免疫賦活剤及びそれを利用した香粧品
WO2002012348A2 (en) 2000-08-03 2002-02-14 Abac R & D Gmbh Isolation of glucan particles and uses thereof
US6531178B2 (en) * 2000-12-08 2003-03-11 Quaker Oats/Rhone-Poulenc Partnership β-glucan process, additive and food product
US7816514B2 (en) 2001-02-16 2010-10-19 Cargill, Incorporated Glucosamine and method of making glucosamine from microbial biomass
US7923437B2 (en) * 2001-02-16 2011-04-12 Cargill, Incorporated Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same
US8222232B2 (en) * 2001-02-16 2012-07-17 Cargill, Incorporated Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass
CN100391439C (zh) * 2001-04-27 2008-06-04 味之素株式会社 免疫增强剂
JP4561098B2 (ja) * 2001-06-01 2010-10-13 味の素株式会社 糖尿病用薬剤
US6811777B2 (en) 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
JP2006504409A (ja) 2002-07-24 2006-02-09 チルドレンズ　ホスピタル　メディカル　センター 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法
AU2003257007A1 (en) * 2002-08-01 2004-02-23 Immusonic, Inc. Beta-glucan containing composites, methods for manufacturing and for using such composites
EP1545208A4 (de) 2002-08-13 2006-04-12 Biopolymer Engineering Inc Verfahren zur verwendung von beta-glucan als strahlenschutzmittel
AU2003295326A1 (en) 2002-09-04 2004-04-23 Cancer therapy using beta glucan and antibodies
US7018986B2 (en) * 2002-09-20 2006-03-28 Immudyne Use of beta glucans for the treatment of osteoporosis and other diseases of bone resorption
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
JP4889944B2 (ja) * 2002-10-29 2012-03-07 コロラド ステート ユニバーシティー リサーチ ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
GB0225502D0 (en) * 2002-11-01 2002-12-11 Zoolife Internat Ltd Therapeutic and prophylactic preparations
NZ542018A (en) * 2003-01-29 2008-04-30 Immudyne Inc Immunopotentiating agent for use in animals
US20060121131A1 (en) * 2003-05-02 2006-06-08 Ceapro Inc. Pharmaceutical compositions comprising cereal beta (1-3) beta (1-4) glucan
EP2517717A1 (de) * 2003-05-02 2012-10-31 Ceapro Inc. Verbessertes Extraktions- und Reinigungsverfahren für Getreide-Beta-(1-3)-Beta-(1-4)-Glucan
PT1663266E (pt) * 2003-08-11 2013-04-30 Lesaffre & Cie Paredes celulares de leveduras para o tratamento ou a prevenção de hiperglicemia ou para a estabilização da glicemia
WO2005065419A2 (en) * 2003-12-29 2005-07-21 Am Biosolutions Method of culturing cells
US20070110737A1 (en) * 2003-12-29 2007-05-17 Allan Mishra Compositions and method for decreasing the appearance of skin wrinkles
US7678780B2 (en) * 2003-12-29 2010-03-16 Allan Mishra Method of treating cancer using platelet releasate
PL1711058T3 (pl) 2004-01-23 2022-02-07 Eden Research Plc Sposoby zabijania nicieni obejmujące aplikację składnika terpenowego
EP1740191A4 (de) * 2004-04-28 2008-07-30 Univ Brigham Young Verwendung von equol zur behandlung von hauterkrankungen
AU2005245190B2 (en) 2004-05-20 2011-07-07 Eden Research Plc Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
US7462268B2 (en) 2004-08-20 2008-12-09 Allan Mishra Particle/cell separation device and compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
US20060079481A1 (en) * 2004-10-08 2006-04-13 Rolf Engstad Method of treating/preventing mucositis
US20090092641A1 (en) * 2004-10-18 2009-04-09 Progressive Bioactivities, Inc. Uses of natural immunobiotic extract
US20050020490A1 (en) * 2004-10-18 2005-01-27 Progressive Bioactives Incorporated A Method of Producing an Economical and Ecologically Sound Natural Immunobiotic Extract for Use as a Health Management Instrument and a Replacement for Growth Promotion Antibiotics in Livestock and Companion Animals.
BRPI0611535B1 (pt) 2005-05-05 2021-11-30 Sensient Flavors Inc Método para processar células de levedura para produzir beta-glucanos e mananas
JP4545063B2 (ja) * 2005-08-05 2010-09-15 キリンホールディングス株式会社 皮膚状態改善組成物
KR100684916B1 (ko) 2005-10-26 2007-02-20 주식회사 글루칸 베타 글루칸을 유효성분으로 포함하는 골절치료용 약학조성물
EP1965809B9 (de) 2005-11-21 2010-07-21 Bioatlantis Limited zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
EP1954130B1 (de) 2005-11-30 2018-06-13 Eden Research Plc Verfahren umfassend terpenmischungen enthaltend thymol und citral
PL2982244T3 (pl) 2005-11-30 2021-08-09 Eden Research Plc Kapsułki owadobójcze zawierające tymol oraz sposoby ich wytwarzania i zastosowania
FR2894771B1 (fr) * 2005-12-21 2008-04-18 Lesaffre & Cie Protection des plantes contre leurs agents pathogenes
US7678393B1 (en) 2006-04-23 2010-03-16 DB Laboratories LLC Mixture composition and method useful for topical and internal application
BRPI0713734A2 (pt) * 2006-06-15 2012-11-06 Biopolymer Engineering Inc Dba Biothera processo para a produção de beta-glucano solúvel, e, composição
KR20090080536A (ko) * 2006-11-02 2009-07-24 가부시키가이샤 아우레오 생체 치유 촉진제
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
WO2008057501A2 (en) * 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
TW200900053A (en) * 2007-02-21 2009-01-01 Biotec Pharmacon Asa Medical uses of glucans
WO2008140744A1 (en) * 2007-05-08 2008-11-20 Biopolymer Engineering, Inc. Dba Biothera, Inc. Particulate-soluble glucan preparation
FI20070471A0 (fi) * 2007-06-13 2007-06-13 Glykos Finland Oy Ravinnelisäkompositiota
ES2394129T3 (es) * 2007-10-25 2013-01-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Construcciones que contienen múltiples casetes de expresión para terapia de cáncer
WO2009055848A1 (en) * 2007-10-31 2009-05-07 Novogen Research Pty Ltd Methods for sterilizing glucans
WO2009103114A1 (en) * 2008-02-19 2009-08-27 Novogen Research Pty Ltd Method for producing a bioactive glucan product substantially free of endotoxin contamination
CN101965367B (zh) * 2008-03-11 2013-07-24 未来纤维技术有限公司 模式度量型光纤传感器
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
WO2010042658A1 (en) 2008-10-07 2010-04-15 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
JP5320965B2 (ja) * 2008-10-09 2013-10-23 ダイソー株式会社 β−１，３−１，６−Ｄ−グルカンを用いた消化管粘膜保護剤または下痢抑制剤
WO2010042991A1 (en) * 2008-10-15 2010-04-22 Novogen Research Pty Ltd Methods of treatment utilising glucan formulations
FI20080665A0 (fi) * 2008-12-18 2008-12-18 Glykos Finland Oy Luonnollisen tyyppiset sakkaridikoostumukset
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20100267661A1 (en) * 2009-03-17 2010-10-21 Immudyne, Inc. Beta glucans and methods of use thereof
US20110129801A1 (en) * 2009-11-27 2011-06-02 Shikha Pramanik Barman Compositions and methods to prevent and treat dry socket post-operatively after tooth extraction surgery
JP6060071B2 (ja) 2010-03-24 2017-01-11 アールエックスアイ ファーマシューティカルズ コーポレーション 皮膚および線維症適用におけるｒｎａ干渉
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
GB201020193D0 (en) * 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
GB201020191D0 (en) * 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan gels
GB201020190D0 (en) 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucans
CZ303500B6 (cs) * 2010-12-08 2012-10-24 Vysoká škola chemicko technologická v Praze Príprava polysacharidové fólie s imunomodulacními úcinky, obsahující beta - (1-3), (1-6)-D-glukan
WO2012120290A2 (en) 2011-03-04 2012-09-13 Sana Pharma As Cosmetic formulations
IN2014DN07419A (de) 2012-02-22 2015-04-24 Algal Scient Corp
GB201220940D0 (en) 2012-11-21 2013-01-02 Eden Research Plc Method P
CN103044572B (zh) * 2013-01-06 2014-11-26 中国农业科学院农产品加工研究所 酵母β-D-葡聚糖的制备方法
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
CN103613682B (zh) * 2013-11-19 2015-08-19 济南大学 一种制备酵母葡聚糖联产甘露聚糖及海藻糖的方法
EP3071031A1 (de) 2013-11-21 2016-09-28 Eden Research Plc Pestizidzusammensetzung
EP3077050B1 (de) 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Verfahren zur behandlung von wundheilung mit chemisch modifizierten oligonukleotiden
CN105980413B (zh) * 2014-02-14 2020-11-10 纳幕尔杜邦公司 用于制备葡聚糖聚合物的葡糖基转移酶
CN105992796A (zh) * 2014-02-14 2016-10-05 纳幕尔杜邦公司 用于粘度调节的聚-α-1,3-1,6-葡聚糖
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
EP3137119B1 (de) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Verfahren zur behandlung von krebs mithilfe von einer nukleinsaüre gegen mdm2
JP2017514908A (ja) 2014-05-01 2017-06-08 アールエックスアイ ファーマシューティカルズ コーポレーション 核酸分子を利用する目の前部における障害の処置のための方法
US20170071973A1 (en) * 2014-05-07 2017-03-16 Mark DEACON-SHAW Extended shelf life wound healing formulation
JP6893594B2 (ja) 2014-07-10 2021-06-23 ハイバーセル，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
CN107106593B (zh) 2014-11-06 2021-05-07 百奥赛诺公司 影响肿瘤微环境的β-葡聚糖方法与组合物
CN104474463A (zh) * 2014-11-26 2015-04-01 陈红芹 一种用于恢复产后骨裂伤的护理膏药
GB201501793D0 (en) 2015-02-03 2015-03-18 Eden Research Plc Encapsulation of high potency active agents
WO2017007813A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
JP2018531037A (ja) 2015-10-19 2018-10-25 アールエックスアイ ファーマシューティカルズ コーポレーション 長い非コードｒｎａを標的とする減少したサイズの自己送達型核酸化合物
DE102016107140A1 (de) * 2016-04-18 2017-10-19 Gea Mechanical Equipment Gmbh Verfahren zur Gewinnung von zumindest einer oder mehrerer beta-Glucan-Verbindungen oder einer beta-Glucanhaltigen Feststoffsuspension aus Hefezellen
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
WO2019142921A1 (ja) 2018-01-19 2019-07-25 日本製紙株式会社 化粧用組成物
WO2021092464A2 (en) 2019-11-08 2021-05-14 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
EP4342477A1 (de) * 2021-05-21 2024-03-27 Asahi Group Holdings, Ltd. Immunstimulator und verfahren zur herstellung einer glucanzusammensetzung
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US11572420B1 (en) 2021-07-30 2023-02-07 Tissue repair ltd Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof
US11384160B1 (en) 2021-07-30 2022-07-12 Tissue repair ltd Method of making a beta glucan compound
CN113679880A (zh) * 2021-08-25 2021-11-23 西北大学 一种裸藻多糖水凝胶敷料及其制备方法和应用
WO2024096877A1 (en) * 2022-11-02 2024-05-10 Biothera, Inc. Dba Immuno Research Inc. Beta-glucan treatment to promote axon regeneration

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5578001A (en) * 1978-12-06 1980-06-12 Hitoshi Ito Polysaccharide-polypeptide combination having beta(1-3), (1-6) glucan structure and its preparation
JPS5576818A (en) * 1978-12-06 1980-06-10 Hitoshi Ito Agent for improving hepatic function
JPS5576817A (en) * 1978-12-06 1980-06-10 Hitoshi Ito Agent for improving blood vessel function
BE883444A (fr) * 1980-05-22 1980-11-24 Sankyo Co Glucanne, son procede de preparation et son application en therapeutique
GB2076418A (en) * 1980-05-22 1981-12-02 Sankyo Co Hydrolyzed polysaccharide
US4728642A (en) * 1982-04-22 1988-03-01 E. R. Squibb & Sons, Inc. Method of treating wounds with granules and dressing
JPS59210901A (ja) * 1983-05-17 1984-11-29 Nippon Kinoko Kenkyusho プロテオグルカン及びそれからなる抗ガン剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
JPS61291509A (ja) * 1985-06-19 1986-12-22 Dainippon Seito Kk 化粧品配合剤
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
JPS6249273A (ja) * 1985-08-28 1987-03-03 Nec Corp 順序回路の試験方法
JPS62205008A (ja) * 1986-03-05 1987-09-09 Bio Bai Daimaru:Kk 化粧品等の添加剤
JPS6317828A (ja) 1986-07-10 1988-01-25 Res Dev Corp Of Japan 骨形成促進剤
US4973581A (en) * 1987-02-20 1990-11-27 Ajinomoto Company, Inc. Glucan derivatives having tumoricidal activity
US4960697A (en) * 1989-01-06 1990-10-02 The Standard Oil Company Recovery of polysaccharides by employing a divalent cation with a water miscible organic solvent
US5084386A (en) * 1989-03-31 1992-01-28 Sri International Production of beta-1,3-glucan in euglena
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
AU650626B2 (en) * 1989-09-08 1994-06-30 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5238925A (en) * 1990-05-09 1993-08-24 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Angiogenic factor isolated from live yeast cell derivatives and its use in treating wounds or burns in mammals
US5278172A (en) * 1992-07-24 1994-01-11 Hennessey Richard K Method and composition for treating tendon or joint inflammation using a vasodilator
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5885632A (en) 1993-12-14 1999-03-23 Nichimo Co., Ltd. Process for preparing a product from a pulse crop as a starting material and a food containing the product prepared from a pulse crop as a starting material
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5824702A (en) 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer

Also Published As

Publication number Publication date
ES2211943T3 (es) 2004-07-16
JPH11501691A (ja) 1999-02-09
EP0815144A4 (de) 2001-01-10
US20040082539A1 (en) 2004-04-29
US20070142320A1 (en) 2007-06-21
EP0815144A1 (de) 1998-01-07
ATE254634T1 (de) 2003-12-15
WO1996028476A1 (en) 1996-09-19
GB9717617D0 (en) 1997-10-22
GB2314850B (en) 1999-07-14
US20060287277A1 (en) 2006-12-21
US7622575B2 (en) 2009-11-24
DE69630779T2 (de) 2004-09-23
US6242594B1 (en) 2001-06-05
GB2314850A (en) 1998-01-14
US7776843B2 (en) 2010-08-17
JP2008063349A (ja) 2008-03-21
US7648968B2 (en) 2010-01-19
JP4197736B2 (ja) 2008-12-17
AUPN166195A0 (en) 1995-04-06
EP0815144B1 (de) 2003-11-19
US20060293278A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
ATE254634T1 (de) Therapeutische verwendungen von glucan
BR9006139A (pt) Composicao aquosa de xampu,processo para tratar cabelo cosmeticamente e processo para fazer uma composicao aquosa de xampu
DE69618787T2 (de) Topische zusammensetzungen mit verbessertem hautgefühl
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
DE122006000010I2 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in derBehandlung von kardiovaskularen Krankheiten
BR0110587A (pt) Polìmeros dispersìveis em água pesada, sensìveis a ìon
BR0115845A (pt) Agentes de tratamento de cabelo cosméticos e dermatológicos
BR9806925A (pt) Emulsão óleo-em-água, uso de uma emusão óleo-em-água, composição cosmética e/ou dermatológica, processo de tratamento cosmético e uso dos derivados de 1,3,5-triazina
ES2167929T3 (es) Composicion cosmetica que contiene una dispersion acuosa de polimero y una emulsion de silicona disilanol y procedimiento.
BR9403637A (pt) Composição com aspecto de gel e tratamentos cosmético e dermatológico
DE69618651T2 (de) Zusammensetzung zur Behandlung von Keratinsubstanzen, die mindestens ein gepfropftes Siliconpolymer und mindestens ein verdickendes Polymer von (Meth)acrylamid oder eines (Methacrylamidderivats enthält, sowie ihre Verwendungen
FR2731907B1 (fr) Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
SE9601395D0 (sv) New therapeutic treatment 1
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
NO962259L (no) Anvendelse av dimeticon for behandling av aphthae og stomatitt
GB2316003A (en) Hair care compositions
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DE69121598T2 (de) Verfahren, um das Verpacken von sterilisiertem Mineralwasser vorzubereiten sowie verpacktes, sterilisiertes Mineralwasser
FR2786394B1 (fr) Extrait de tourteau de graine de noix, composition cosmetique comprenant ledit extrait et applications
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
ATE294568T1 (de) Zusammensetzung zur behandlung von verbrennungen
FR2811572B1 (fr) Utilisation de cyclodextrines polysulfatees pour le traitement de l'arthrose
SE9403861D0 (sv) Novel medicinal use
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 815144

Country of ref document: EP

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, DE

R081 Change of applicant/patentee

Ref document number: 815144

Country of ref document: EP

Owner name: TR THERAPEUTICS, INC., US

Free format text: FORMER OWNER: NOVOGEN RESEARCH PTY. LTD., NORTH RYDE, AU

Effective date: 20121030

R082 Change of representative

Ref document number: 815144

Country of ref document: EP

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, DE

Effective date: 20121030